The abstract is read at the publisher; the summary is JClub's.
Chemotherapy plus cetuximab in metastatic colorectal cancer is linked to substantially higher grade ≥3 rash (21% vs 0.5%) and greater rash adverse event load versus chemotherapy alone.
- Why it matters: Standard single-worst CTCAE grading can miss chronic or recurrent toxicity burden, limiting tolerability comparisons when ongoing side effects matter for decision-making.
- What they did: Pooled 2 randomized first-line trials in the ARCAD database (n=1302) and used a longitudinal toxicity framework to assess grade ≥3 events, time to maximum grade, early onset (≤6 weeks), and adverse event load.
- The result: Cetuximab increased early-onset maximum rash (67% vs 34%) and kept rash AEL higher within maximum-grade strata; for HFS, higher overall AEL reflected grade distribution rather than within-grade chronicity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.